Vinge, in cooperation with Dechert LLP as lead legal advisor, advised Valneva SE in connection with its acquisition of Crucell Sweden AB, the Nordics vaccine distribution business of the seller (Crucell Holland B.V.) and all assets, licenses and privileges related to Dukoral®, a vaccine against cholera and, in some countries, diarrhea caused by ETEC. Valneva is a Lyon based biotechnology company listed at Euronext Paris and at the Vienna stock exchange. The consideration amounted to € 45 million and the acquisition was completed on 9 February 2015.
Vinge advised Valneva on Swedish law matters. Vinge’s team consists of M&A partner Peter Sundgren, associates Johanna Wiberg and Kajsa Hallner (M&A), Anders Morén and Josefin Larsson (banking & finance), and Amanda Knutsson and David Andersson (capital markets).